Astellas Pharma Inc. (ALPMY)
| Previous Close | 10.16 |
| Open | 10.03 |
| Bid | 10.02 x 40000 |
| Ask | 10.05 x 40000 |
| Day's Range | 10.02 - 10.05 |
| 52 Week Range | 9.15 - 16.64 |
| Volume | |
| Avg. Volume | 349,319 |
| Market Cap | 17.967B |
| Beta (5Y Monthly) | 0.30 |
| PE Ratio (TTM) | 167.00 |
| EPS (TTM) | 0.06 |
| Earnings Date | Jul 30, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | 0.45 (4.50%) |
| Ex-Dividend Date | Sept 28, 2023 |
| 1y Target Est | 12.00 |
PR NewswireU.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the company's resubmission of the Biologics License Application (BLA) for zolbetuximab, a first-in-class investigational claudin (CLDN) 18.2-targeted monoclonal antibody, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesopha
- PR Newswire
Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it signed a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA) to begin discussions on the creation of an innovative cell therapy ecosystem through the integration of pharmaceutical and robotics technologies. This memorandum is legally non-binding and will lead to further specific discussions between the two companies in the future.
- PR Newswire
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4. A total of 16 abstracts will be presented, including new data from pivotal trials supporting ongoing regulatory reviews. The volume of data being presented by Astellas reinforces its commitment to changing the cou
